ProMis Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto
Ontario
M4S 3E2
United States
Website: http://promisneurosciences.com/
99 articles with ProMis Neurosciences, Inc.
-
ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
6/19/2019
Internationally recognized leader in neurodegenerative diseases to advise on programs selectively targeting the toxic oligomer
-
ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference
6/5/2019
Neurodegenerative Diseases: New Insights and Therapeutic Opportunities to advance discussion about therapies for Alzheimer's disease among world's leading researchers
-
ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases
5/29/2019
ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is participating in the JLABS @ Toronto conference, "Science 1st: Common Pathways and Mechanisms in Neurodegenerative Diseases" on May 30, 2019.
-
ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau
5/28/2019
Pipeline offers critical "one-two punch" in potential treatment arsenal for Alzheimer's disease
-
ProMIS Neurosciences Announces First Quarter 2019 Results
5/14/2019
Company continues to show significant progress on developing highly selective antibodies targeting root cause of Alzheimer's and Parkinson's diseases and ALS
-
ProMIS Neurosciences to Participate in the Think Equity Investor Conference
4/23/2019
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
-
ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019
3/26/2019
Company to showcase innovative programs addressing urgent need for disease-modifying therapies selectively targeting toxic oligomers in Alzheimer's and Parkinson's diseases and ALS
-
The debacle raised three broad questions: What will Biogen do next? Is the amyloid theory of Alzheimer’s now dead? And what else is going on in the Alzheimer’s drug development arena?
-
Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
3/21/2019
Discontinued aducanumab phase 3 studies emphasize urgent need for therapies that target the toxic oligomer with exacting precision
-
ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD 2019 Conference
3/19/2019
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present data for new antibody candidates that show stringent selectivity for the toxic forms of alpha-synuclein, considered a root cause of Parkinson's disease
-
ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
3/15/2019
ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced its operational and financial results for the year ended December 31, 2018.
-
ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors
2/21/2019
Former Sanofi U.S. Chairman to provide guidance and assistance to ProMIS business development strategies and partnering plans
-
Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease
1/31/2019
Discontinued crenezumab phase 3 studies underscore urgent need for therapies that target the toxic oligomer with extraordinary precision
-
ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
1/17/2019
Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs
-
ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China Focus@JPMWeek
12/18/2018
ProMIS to showcase its Alzheimer's, Parkinson's and ALS programs at notable biotech investor events
-
ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
12/17/2018
Dr. Rudolph Tanzi is a neuroscientist and geneticist with scientific expertise in Alzheimer's disease and brain health.
-
ProMIS Neurosciences Issues Year-to Date Update, Highlighting 2018 Accomplishments
11/20/2018
Development of therapeutic antibodies for Alzheimer's disease, Parkinson's disease and ALS are top priorities for drug development and potential partnering
-
ProMIS Neurosciences Announces Third Quarter 2018 Results
11/13/2018
ProMIS Neurosciences, Inc. today announced its operational and financial results for the three and nine months ended September 30, 2018.
-
ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer's Disease
11/6/2018
Narrated white paper reveals lessons learned from 15 years of drug development; pressing need to selectively target the toxic oligomer.
-
ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer's Disease and Other Dementias
10/31/2018
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the identification of novel targets on misfolded, pathological forms of tau.